Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Frank Martin Sacks, M.D.

Co-Author

This page shows the publications co-authored by Frank Sacks and Eugene Braunwald.
Connection Strength

2.004
  1. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002 Mar 26; 105(12):1424-8.
    View in: PubMed
    Score: 0.249
  2. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000 Oct 17; 102(16):1886-92.
    View in: PubMed
    Score: 0.225
  3. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998 Apr 21; 97(15):1446-52.
    View in: PubMed
    Score: 0.189
  4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 03; 335(14):1001-9.
    View in: PubMed
    Score: 0.170
  5. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) Am J Cardiol. 1991 Dec 01; 68(15):1436-46.
    View in: PubMed
    Score: 0.122
  6. HMG CoA reduction in patients with average cholesterol concentrations. Clin Chem. 2011 Jul; 57(7):1072-3.
    View in: PubMed
    Score: 0.117
  7. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29; 51(4):435-43.
    View in: PubMed
    Score: 0.093
  8. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):562-7.
    View in: PubMed
    Score: 0.093
  9. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002 May 21; 105(20):2341-6.
    View in: PubMed
    Score: 0.063
  10. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52.
    View in: PubMed
    Score: 0.060
  11. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000 Oct 17; 102(16):1893-900.
    View in: PubMed
    Score: 0.056
  12. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000 May 09; 101(18):2149-53.
    View in: PubMed
    Score: 0.055
  13. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 Jul 20; 100(3):230-5.
    View in: PubMed
    Score: 0.052
  14. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999 Jul; 34(1):106-12.
    View in: PubMed
    Score: 0.051
  15. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999 Jan 19; 99(2):216-23.
    View in: PubMed
    Score: 0.050
  16. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol. 1999 Jan; 33(1):125-30.
    View in: PubMed
    Score: 0.050
  17. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998 Dec 08; 98(23):2513-9.
    View in: PubMed
    Score: 0.049
  18. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998 Nov 01; 129(9):681-9.
    View in: PubMed
    Score: 0.049
  19. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 Sep 01; 98(9):839-44.
    View in: PubMed
    Score: 0.049
  20. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998 Jul; 32(1):140-6.
    View in: PubMed
    Score: 0.048
  21. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271.
    View in: PubMed
    Score: 0.038
  22. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006 Jun 17; 332(7555):1426.
    View in: PubMed
    Score: 0.021
  23. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke. 2005 Nov; 36(11):2346-50.
    View in: PubMed
    Score: 0.020
  24. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1405-10.
    View in: PubMed
    Score: 0.020
  25. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003 Oct 15; 42(8):1446-53.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.